Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Receivables - Net: 2010-2024

Historic Receivables - Net for Anika Therapeutics (ANIK) over the last 15 years, with Dec 2024 value amounting to $24.3 million.

  • Anika Therapeutics' Receivables - Net fell 25.45% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year decrease of 25.45%. This contributed to the annual value of $24.3 million for FY2024, which is 10.00% down from last year.
  • Anika Therapeutics' Receivables - Net amounted to $24.3 million in FY2024, which was down 10.00% from $27.0 million recorded in FY2023.
  • Over the past 5 years, Anika Therapeutics' Receivables - Net peaked at $36.2 million during FY2022, and registered a low of $24.1 million during FY2020.
  • Over the past 3 years, Anika Therapeutics' median Receivables - Net value was $27.0 million (recorded in 2023), while the average stood at $29.2 million.
  • Per our database at Business Quant, Anika Therapeutics' Receivables - Net climbed by 29.80% in 2021 and then decreased by 25.41% in 2023.
  • Yearly analysis of 5 years shows Anika Therapeutics' Receivables - Net stood at $24.1 million in 2020, then climbed by 29.80% to $31.3 million in 2021, then grew by 15.82% to $36.2 million in 2022, then decreased by 25.41% to $27.0 million in 2023, then dropped by 10.00% to $24.3 million in 2024.